Table 3.

GRADE summary of findings for serious adverse events for different comparisons

	Study results and measurements	Absolute difference per 1000 patients (95% CI)	Certainty in effect estimates	Plain language summary
REGN-EB3 versus standard care	Risk difference 0·016 (95% CI −0·061 to 0·093); based on indirect evidence	16 (−61 to 93)	Very low*†	Whether REGN-EB3 increases the prevalence of serious adverse events compared with standard care is very uncertain
mAb114 versus standard care	Risk difference 0·016 (95% CI −0·061 to 0·093); based on indirect evidence	16 (−61 to 93)	Very low*†	Whether mAb114 increases the prevalence of serious adverse events compared with standard care is very uncertain
ZMapp versus standard care	Risk difference 0·028 (95% CI −0·046 to 0·102); based on data from 71 participants in one study	28 (−46 to 102)	Very low*†	Whether ZMapp increases the prevalence of serious adverse events compared with standard care is very uncertain
Remdesivir versus standard care	Risk difference 0·022 (95% CI −0·056 to 0·099); based on indirect evidence	22 (−56 to 99)	Very low*†	Whether remdesivir increases the prevalence of serious adverse events compared with standard care is very uncertain
REGN-EB3 versus mAb114	Risk difference 0·000 (95% CI −0·012 to 0·012); based on data from 329 participants in one study	0 (−12 to 12)	Moderate*	There is probably little or no difference between REGN-EB3 and mAb114 in the prevalence of serious adverse events
REGN-EB3 versus ZMapp	Risk difference −0·012 (95% CI −0·032 to 0·008); based on data from 324 participants in one study	−12 (−32 to 8)	Low*‡	There might be little or no difference in the prevalence of serious adverse events between REGN-EB3 and ZMapp
REGN-EB3 versus remdesivir	Risk difference −0·006 (95% CI −0·022 to 0·011); based on data from 330 participants in one study	−6 (−22 to 11)	Low*‡	There might be little or no difference in the prevalence of serious adverse events between REGN-EB3 and remdesivir
mAb114 versus ZMapp	Risk difference −0·012 (95% CI −0·032 to 0·008); based on data from 343 participants in one study	−12 (−32 to 8)	Low*‡	There might be little or no difference in the prevalence of serious adverse events between mAb114 and ZMapp
mAb114 versus remdesivir	Risk difference −0·006 (95% CI −0·021 to 0·010); based on data from 349 participants in one study	−6 (−21 to 10)	Low*‡	There might be little or no difference in the prevalence of serious adverse events between mAb114 and remdesivir
ZMapp versus remdesivir	Risk difference 0·006 (95% CI −0·017 to 0·029); based on data from 344 participants in one study	6 (−17 to 29)	Low*‡	There might be little or no difference in the prevalence of serious adverse events between ZMapp and remdesivir

GRADE=Grading of Recommendations Assessment, Development and Evaluation.

^*Rated down for risk of bias.

^†Rated down two levels for imprecision.

^‡Rated down for imprecision.